OQROGet OQRO Pro
Insider trade

Corcept Therapeutics (CORT)Director sold ~$313K

James N Wilson, Director at Corcept Therapeutics, sold ~$313K of Corcept Therapeutics shares.

~$313K
Approx. value · 2,800 sh @ $111.70
1.06M
Holds after · shares reported
Traded
Sep 15, 2026
Filed
Sep 17, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Jul 15, 2026Insider · 2 peopleInsiders: 8 sales (~$4.4M)
  2. Jul 29, 2026Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors
  3. Jul 30, 2026Insider · 1 personInsiders: 13 sales (~$9.2M)
  4. Aug 3, 2026Insider · 2 peopleInsiders: 2 sales (~$2.5M)
  5. Aug 4, 2026InsiderOfficer sold ~$419K of CORT shares in the open market
  6. Aug 10, 2026Insider · 2 peopleInsiders: 3 sales (~$2.0M)
  7. Aug 14, 2026Insider · 2 peopleInsiders: 4 sales (~$1.5M)
  8. Aug 17, 2026InsiderOfficer sold ~$1.16M of CORT shares in the open market
  9. Aug 18, 2026Insider · 1 personInsiders: 4 sales (~$12.3M)
  10. Aug 25, 2026Insider · 1 personInsiders: 2 sales (~$3.9M)
  11. Aug 26, 2026InsiderDirector sold ~$3.27M of CORT shares in the open market
  12. Sep 1, 2026Insider · 1 personInsiders: 3 sales (~$2.9M)
  13. Sep 2, 2026Insider · 1 personInsiders: 7 sales (~$6.5M)
  14. Sep 14, 2026Insider · 1 personInsiders: 2 sales (~$1.1M)
  15. Sep 15, 2026 · this disclosureInsiderDirector sold ~$313K of CORT shares in the open market

What came next

  1. Sep 15, 2026Insider · 1 personInsiders: 2 sales (~$794K)
  2. Sep 16, 2026InsiderOfficer sold ~$30K of CORT shares in the open market
  3. Sep 22, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On September 22, 2026, Sean Maduck, the President of Corcept Endocrinology, notified the Board of Directors of Corcept Therapeutics Incorporated (the “Company”) of his decision to resign effective as of October 1, 2026.”
  4. Oct 1, 2026Insider · 2 peopleInsiders: 2 sales (~$141K)
  5. Oct 2, 2026Insider · 3 peopleInsiders: 7 sales (~$4.9M)
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Corcept Therapeutics

For Corcept Therapeutics, OQRO holds 64 insider filings (SEC Form 4 or Form 144) and 5 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its CORT page.

Other recent filings by James N Wilson, Director

The full history of James N Wilson, Director is on the profile page.

How this filing works

Other disclosures at Corcept Therapeutics

Everything OQRO holds on this company is on its CORT page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO ProAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data